IGF2 and neoplasm: Although it is difficult to precisely estimate, varying tumour risks are associated with BWS molecular subgroups: patients with H19/IGF2:IG DMR GOM have the highest risk (28% risk), followed by those with segmental UPD(11)pat (16% risk), loss-of-function CDKN1C variants (6.9% risk), and lastly, KCNQ1OT1:TSS DMR LOM cases (2.6% risk) [21].